These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 54544)

  • 21. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S; Jørgensen J
    Acta Med Scand; 1978; 203(6):471-6. PubMed ID: 665313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of prothrombin complex concentrates in the treatment of a hemophilic patient with an inhibitor of factor VIII.
    Sonoda T; Solomon A; Krauss S; Cruz P; Jones FS; Levin J
    Blood; 1976 Jun; 47(6):983-9. PubMed ID: 1276480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
    Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
    Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of facoor VIII and factor IX concentrates during surgery.
    George JN; Breckenridge RT
    JAMA; 1970 Nov; 214(9):1673-6. PubMed ID: 5536529
    [No Abstract]   [Full Text] [Related]  

  • 27. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 28. Acquired circulating anticoagulant in classical hemophilia: treatment with prothrombin concentrate.
    Rosen R; Mikel T; Corrigan JJ
    Ariz Med; 1977 May; 34(5):340-2. PubMed ID: 883905
    [No Abstract]   [Full Text] [Related]  

  • 29. Prophylaxis in children with haemophilia - the Polish experience.
    Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
    Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
    [No Abstract]   [Full Text] [Related]  

  • 30. [Viral hepatitis in hemophiliac patients treated with commercial concentrates of factors VIII and IX].
    Miranda ML; Lissen E; Vinuesa M; Jiménez JM; García de Pesquera F; Leal M
    Med Clin (Barc); 1985 Apr; 84(13):516-9. PubMed ID: 3923278
    [No Abstract]   [Full Text] [Related]  

  • 31. Life-threatening sublingual hematoma in a severely hemophilic patient with factor VIII inhibitor.
    Takeuchi M; Shikimori M; Kaneda T
    J Oral Maxillofac Surg; 1986 May; 44(5):401-3. PubMed ID: 3084733
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. There is no correlation between vitamin K dependent coagulant content and clinical effectiveness of activated and standard factor IX complex concentrates.
    Aronson DL
    Prog Clin Biol Res; 1984; 150():243-50. PubMed ID: 6379676
    [No Abstract]   [Full Text] [Related]  

  • 34. Letter: Factor-VIII inhibitor bypassing activity.
    Pollock A; Lewis MJ
    Lancet; 1976 Jul; 2(7975):43-4. PubMed ID: 59103
    [No Abstract]   [Full Text] [Related]  

  • 35. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
    Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
    [No Abstract]   [Full Text] [Related]  

  • 36. Virucidal treatment of clotting factor concentrates.
    Mannucci PM; Colombo M
    Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of anti-factor VIII antibodies.
    Blatt PM; White GC; McMillan CW; Roberts HR
    Thromb Haemost; 1977 Aug; 38(2):514-23. PubMed ID: 579493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic properties and safety of recombinant factor VIII and factor IX.
    Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
    Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Inhibitors and "bypass" therapy in hemophilia].
    Fukutake K; Fukutake K
    Nihon Rinsho; 1981; 39(12):3688-99. PubMed ID: 6803034
    [No Abstract]   [Full Text] [Related]  

  • 40. Recombinant clotting factors in the treatment of hemophilia.
    Lee C
    Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.